Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGPL1 | O95470 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26285054 | 0.85 | — | — | |
| SCHEMBL21524933 | 0.81 | — | — | |
| SCHEMBL21524935 | 0.81 | — | — | |
| SCHEMBL16381727 | 0.77 | SGPL1 (0.36) | SGPL1 | |
| SCHEMBL17032229 | 0.75 | SGPL1 (0.45) | SGPL1 | |
| SCHEMBL17593815 | 0.73 | — | — | |
| SCHEMBL16301868 | 0.73 | — | — | |
| SCHEMBL25317098 | 0.72 | CA1 (0.31) | SGPL1 | |
| SCHEMBL13649078 | 0.72 | — | — | |
| SCHEMBL13713169 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342093-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
| US-9771382-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160304539-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-9403850-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9376454-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160016978-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |
| US-20150224125-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | disclosed |
| US-9040504-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140194386-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342093-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | SGPL1 1843/4885 |
| US-20160016978-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | SGPL1 1843/4885 |
| US-20140194386-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | SGPL1 1843/4885 |
| US-20150224125-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | SGPL1 1843/4885 |
| US-20160304539-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | SGPL1 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.